ALLMedicine™ Papillary Renal Cell Carcinoma Center
Research & Reviews 285 results
https://clinicaltrials.gov/ct2/show/NCT03091192
May 20th, 2022 - This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is ef...
https://doi.org/10.1016/j.mayocp.2022.03.013
Mayo Clinic Proceedings; Gupta S, Erickson LA
May 6th, 2022 - Papillary Renal Cell Carcinoma With "Drop Metastasis" (Tumor Seeding) Involving the Distal Ureter.|2022|Gupta S,Erickson LA,|pathology,pathology,pathology,pathology,
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026678
Journal of Medical Case Reports; Chou YC, Lee WY et. al.
Apr 23rd, 2022 - Renal adenomatosis is a rare disease that presents as multiple papillary adenomas in the bilateral kidneys. Moreover, papillary adenoma is considered a precursor to papillary renal cell carcinoma. Therefore, patients with renal adenomatosis may ha...
https://doi.org/10.1007/s11912-022-01269-1 10.1016/j.eururo.2016.02.029 10.1016/S1470-2045(15)00515-X 10.1016/j.eururo.2015.10.049 10.1016/j.arcmed.2020.08.003 10.1016/j.ctrv.2021.102191 10.1097/PAS.0000000000000247 10.1016/S1470-2045(18)30907-0 10.1016/S0140-6736(21)00152-5 10.1001/jamaoncol.2020.2218 10.1200/JCO.20.02363 10.1200/JCO.20.02365 10.1002/cncr.33033 10.1200/JCO.2019.37.7_suppl.545 10.1200/JCO.2021.39.15_suppl.4509 10.1016/j.ejca.2021.04.009 10.1016/j.ccr.2014.07.014 10.1001/jamanetworkopen.2020.21869 10.1007/s11255-015-1161-3 10.1159/000127387 10.1002/cncr.24864 10.1093/annonc/mdr586 10.1016/j.eururo.2012.06.043 10.1093/annonc/mdu445 10.1111/cas.13996 10.1016/j.juro.2013.02.035 10.1016/j.eururo.2007.01.070 10.1016/j.eururo.2015.06.019 10.1016/j.juro.2007.01.063 10.1200/JCO.2016.67.9084 10.1111/bju.13705 10.1016/j.humpath.2019.08.005 10.1002/gcc.22798 10.1038/modpathol.2013.208 10.1097/PAS.0b013e31824dd972 10.1111/his.13866 10.1158/2326-6066.CIR-17-0475 10.1002/cncr.25512 10.1038/ncomms13131 10.1016/j.urolonc.2016.01.005 10.1016/j.ejca.2020.06.008
Current Oncology Reports; Maughan BL
Apr 20th, 2022 - Historically, kidney cancer was diagnosed as either clear cell renal carcinoma (ccRCC) or non-clear cell renal carcinoma (nccRCC). With further research into the pathophysiology of nccRCC, multiple distinct subtypes have emerged creating distinct ...
https://doi.org/10.1016/j.clgc.2022.03.004
Clinical Genitourinary Cancer; Toide M, Saito K et. al.
Apr 13th, 2022 - C-reactive protein is a useful biomarker for screening renal cell carcinoma (RCC); however, its significance in papillary RCC is unclear. We assessed the prognostic effect of serum C-reactive protein levels in patients with surgically treated non-...
Clinicaltrials.gov 7 results
https://clinicaltrials.gov/ct2/show/NCT03091192
May 20th, 2022 - This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is ef...
https://clinicaltrials.gov/ct2/show/NCT05287945
Mar 18th, 2022 - This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 40 patients. T...
https://clinicaltrials.gov/ct2/show/NCT02019693
Dec 21st, 2021 - Background: Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non famili...
https://clinicaltrials.gov/ct2/show/NCT02127710
Apr 19th, 2021 - The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled. This group is considered sufficient to provide preliminary assessment of the anti-tumour activity of AZD6094 in the form of non-binding futility analysis. I...
https://clinicaltrials.gov/ct2/show/NCT00541008
Feb 21st, 2021 - OBJECTIVES: Primary To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary To evaluate the safety of this drug in these patients. To de...
News 10 results
https://www.onclive.com/view/frontline-mrcc-paradigm-crowds-among-immune-based-treatment-options
Mar 13th, 2021 - The emergence of multiple combination regimens with immunotherapy and tyrosine kinase inhibitors (TKIs) has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma (mRCC); however, without head-to-head comparative...
https://www.medscape.com/viewarticle/945955
Feb 17th, 2021 - When treating metastatic papillary renal cell carcinoma (RCC), cabozantinib outperforms the current standard of care, according to results from the Southwest Oncology Group (SWOG) 1500 trial. Compared with the VEGFR-2 inhibitor sunitinib, the MET ...
https://www.mdedge.com/hematology-oncology/article/235981/genitourinary-cancer/cabozantinib-could-be-new-standard-papillary
Susan London
Feb 16th, 2021 - When treating metastatic papillary renal cell carcinoma (RCC), cabozantinib outperforms the current standard of care, according to results from the Southwest Oncology Group (SWOG) 1500 trial. Dr.
https://www.onclive.com/view/when-to-consider-referral-to-a-genetic-counselor-for-lesser-known-cancer-syndromes
Dec 5th, 2020 - Abstract This article reviews two newly described cancer syndromes: DICER1 and BAP1 tumor predisposition syndrome, and four uncommon syndromes: Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome, Hereditary Leiomyomatosis and Renal Cell Ca...
https://www.medscape.com/viewarticle/931729
Jun 8th, 2020 - NEW YORK (Reuters Health) - Savolitinib appears to improve outcomes in patients with MET-driven papillary renal-cell carcinoma (PRCC) compared with sunitinib, the standard of care, according to results from the SAVOIR randomized clinical trial. Th...
